Mouse models in squamous cell lung cancer: impact for drug discovery

Aditi P. Singh, Diego Adrianzen Herrera, Yifei Zhang, Roman Perez-Soler, Haiying Cheng

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Squamous cell lung cancer (SQCLC) is the second most common subtype of non-small cell lung cancer (NSCLC) and has limited therapeutic options. Its development is likely a result of a multistep process in response to chronic tobacco exposure, involving sequential metaplasia, dysplasia and invasive carcinoma. Its complex genomic landscape has recently been revealed but no driver mutations have been validated that could lead to molecularly targeted therapy as have emerged in lung adenocarcinoma. Few preclinical murine models exist for testing and developing novel therapeutics in SQCLC. Areas covered: This review discusses the pathophysiology and molecular underpinnings of SQCLC that have limited the development of animal models. It then explores the advantages and limitations of a variety of existing mouse models and illustrates their potential application in drug discovery and chemoprevention. Expert opinion: There are several challenges in the development of mouse models for SQCLC, such as lack of validated driver genetic alterations, unclear cell of origin, and difficulty in reproducing the sophisticated tumor microenvironment of human disease. Nevertheless, several successful SQCLC murine models have emerged, especially Patient Derived Xenografts (PDXs) and Genetically Engineered Mouse Models (GEMMs). Continued efforts are needed to generate more SQCLC animal models to better understand its carcinogenesis and metastasis and to further test novel therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)347-358
Number of pages12
JournalExpert Opinion on Drug Discovery
Volume13
Issue number4
DOIs
StatePublished - Apr 3 2018

Fingerprint

Squamous Cell Neoplasms
Drug Discovery
Lung Neoplasms
Animal Models
Tumor Microenvironment
Chemoprevention
Metaplasia
Expert Testimony
Therapeutics
Heterografts
Non-Small Cell Lung Carcinoma
Tobacco
Carcinogenesis
Neoplasm Metastasis
Carcinoma
Mutation

Keywords

  • mouse models
  • murine models
  • Squamous cell lung cancer
  • xenografts

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Mouse models in squamous cell lung cancer : impact for drug discovery. / Singh, Aditi P.; Adrianzen Herrera, Diego; Zhang, Yifei; Perez-Soler, Roman; Cheng, Haiying.

In: Expert Opinion on Drug Discovery, Vol. 13, No. 4, 03.04.2018, p. 347-358.

Research output: Contribution to journalReview article

Singh, Aditi P. ; Adrianzen Herrera, Diego ; Zhang, Yifei ; Perez-Soler, Roman ; Cheng, Haiying. / Mouse models in squamous cell lung cancer : impact for drug discovery. In: Expert Opinion on Drug Discovery. 2018 ; Vol. 13, No. 4. pp. 347-358.
@article{e5f8c514f3df45799419b3fc8b1e3393,
title = "Mouse models in squamous cell lung cancer: impact for drug discovery",
abstract = "Introduction: Squamous cell lung cancer (SQCLC) is the second most common subtype of non-small cell lung cancer (NSCLC) and has limited therapeutic options. Its development is likely a result of a multistep process in response to chronic tobacco exposure, involving sequential metaplasia, dysplasia and invasive carcinoma. Its complex genomic landscape has recently been revealed but no driver mutations have been validated that could lead to molecularly targeted therapy as have emerged in lung adenocarcinoma. Few preclinical murine models exist for testing and developing novel therapeutics in SQCLC. Areas covered: This review discusses the pathophysiology and molecular underpinnings of SQCLC that have limited the development of animal models. It then explores the advantages and limitations of a variety of existing mouse models and illustrates their potential application in drug discovery and chemoprevention. Expert opinion: There are several challenges in the development of mouse models for SQCLC, such as lack of validated driver genetic alterations, unclear cell of origin, and difficulty in reproducing the sophisticated tumor microenvironment of human disease. Nevertheless, several successful SQCLC murine models have emerged, especially Patient Derived Xenografts (PDXs) and Genetically Engineered Mouse Models (GEMMs). Continued efforts are needed to generate more SQCLC animal models to better understand its carcinogenesis and metastasis and to further test novel therapeutic strategies.",
keywords = "mouse models, murine models, Squamous cell lung cancer, xenografts",
author = "Singh, {Aditi P.} and {Adrianzen Herrera}, Diego and Yifei Zhang and Roman Perez-Soler and Haiying Cheng",
year = "2018",
month = "4",
day = "3",
doi = "10.1080/17460441.2018.1437137",
language = "English (US)",
volume = "13",
pages = "347--358",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Mouse models in squamous cell lung cancer

T2 - impact for drug discovery

AU - Singh, Aditi P.

AU - Adrianzen Herrera, Diego

AU - Zhang, Yifei

AU - Perez-Soler, Roman

AU - Cheng, Haiying

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Introduction: Squamous cell lung cancer (SQCLC) is the second most common subtype of non-small cell lung cancer (NSCLC) and has limited therapeutic options. Its development is likely a result of a multistep process in response to chronic tobacco exposure, involving sequential metaplasia, dysplasia and invasive carcinoma. Its complex genomic landscape has recently been revealed but no driver mutations have been validated that could lead to molecularly targeted therapy as have emerged in lung adenocarcinoma. Few preclinical murine models exist for testing and developing novel therapeutics in SQCLC. Areas covered: This review discusses the pathophysiology and molecular underpinnings of SQCLC that have limited the development of animal models. It then explores the advantages and limitations of a variety of existing mouse models and illustrates their potential application in drug discovery and chemoprevention. Expert opinion: There are several challenges in the development of mouse models for SQCLC, such as lack of validated driver genetic alterations, unclear cell of origin, and difficulty in reproducing the sophisticated tumor microenvironment of human disease. Nevertheless, several successful SQCLC murine models have emerged, especially Patient Derived Xenografts (PDXs) and Genetically Engineered Mouse Models (GEMMs). Continued efforts are needed to generate more SQCLC animal models to better understand its carcinogenesis and metastasis and to further test novel therapeutic strategies.

AB - Introduction: Squamous cell lung cancer (SQCLC) is the second most common subtype of non-small cell lung cancer (NSCLC) and has limited therapeutic options. Its development is likely a result of a multistep process in response to chronic tobacco exposure, involving sequential metaplasia, dysplasia and invasive carcinoma. Its complex genomic landscape has recently been revealed but no driver mutations have been validated that could lead to molecularly targeted therapy as have emerged in lung adenocarcinoma. Few preclinical murine models exist for testing and developing novel therapeutics in SQCLC. Areas covered: This review discusses the pathophysiology and molecular underpinnings of SQCLC that have limited the development of animal models. It then explores the advantages and limitations of a variety of existing mouse models and illustrates their potential application in drug discovery and chemoprevention. Expert opinion: There are several challenges in the development of mouse models for SQCLC, such as lack of validated driver genetic alterations, unclear cell of origin, and difficulty in reproducing the sophisticated tumor microenvironment of human disease. Nevertheless, several successful SQCLC murine models have emerged, especially Patient Derived Xenografts (PDXs) and Genetically Engineered Mouse Models (GEMMs). Continued efforts are needed to generate more SQCLC animal models to better understand its carcinogenesis and metastasis and to further test novel therapeutic strategies.

KW - mouse models

KW - murine models

KW - Squamous cell lung cancer

KW - xenografts

UR - http://www.scopus.com/inward/record.url?scp=85043492647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043492647&partnerID=8YFLogxK

U2 - 10.1080/17460441.2018.1437137

DO - 10.1080/17460441.2018.1437137

M3 - Review article

C2 - 29394493

AN - SCOPUS:85043492647

VL - 13

SP - 347

EP - 358

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 4

ER -